Diagnostic Financings Are Robust, Fueled by COVID-19 and Precision Medicine

article image

Private investors poured more than $8 billion into diagnostics companies between January 2020 and September 30, 2021, envisioning myriad opportunities for innovative COVID-19 testing technologies and precision medicine tests that help optimize individual treatment regimens.

Private investors deployed roughly $8.4 billion in capital into diagnostics from January 2020 through the first nine months of 2021, with preferences for companies tied to innovative COVID-19 testing technologies and tech-enabled precision medicine strategies around optimizing individual treatment regimens.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: